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Abstract Mandibulofacial dysostosis with microcephaly
(MFDM) is a rare autosomal dominant condition that was first
described in 2006. The causative gene, EFTUD2, identified in
2012. We report on a family that initially presented to a pedi-
atric genetics clinic in the 1980s for evaluation of multiple
congenital anomalies. Re-evaluation of one member thirty
years later resulted in a phenotypic and molecularly confirmed
diagnosis of MFDM. This family’s clinical histories and the
novel EFTUD2 variant identified, c.1297_1298delAT
(p.Met433Valfs*17), add to the literature about MFDM.
This case presented several genetic counseling challenges
and highlights that Bthe patient^ can be multiple family mem-
bers. We discuss testing considerations for an unknown disor-
der complicated by the time constraint of the patient’s daugh-
ter’s pregnancy and how the diagnosis changed previously
provided recurrence risks. Of note, 1) the 1980s clinic visit
letters provided critical information about affected family
members and 2) the patient’s husband’s internet search of his
wife’s clinical features also yielded the MFDM diagnosis,
illustrating the power of the internet in the hands of patients.
Ultimately, this case emphasizes the importance of re-
evaluation given advances in genetics and the value of a
genetic diagnosis for both patient care and risk determination
for family members.
Keywords Mandibulofacial dysostosis withmicrocephaly
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Introduction
Advances in genetic testing have resulted in the identification
of causative genes for genetic syndromes that previously had to
solely rely on clinical criteria for diagnosis. Mandibulofacial
dysostosis with microcephaly (MFDM) is one of those syn-
dromes and was first described in a cohort of 4 unrelated
Brazilian patients (Guion-Almeida et al. 2006; Lines et al.
2012). Themajor criteria ofMFDM (OMIM# 610536) include
mandibulofacial dysostosis, microcephaly, malformations of
the ear, tracheoesophageal fistula/esophageal atresia and
characteristic dysmorphic features (Table 1) (Lines et al.
2012). A diagnosis of MFDM should be suspected in
individuals with 3 or more of these major features
(Lines et al. 2012, 2014). In 2009, investigation of the
first familial case of an affected mother and son suggested
that MFDM was inherited in either an X-linked or auto-
somal dominant manner (Guion-Almeida et al. 2009).
In 2012, EFTUD2 was identified as the causative gene
through whole exome sequencing in four unrelated affected
individuals (Lines et al. 2012). The EFTUD2 gene, located at
17q21.31, encodes a GTPase which is a component in the
spliceosome complex (Fabrizio et al. 1997). The gene con-
tains 29 exons and is 972 amino acids in length (Aken et al.
2016). Themajority of the pathogenic variants inEFTUD2 are
nonsense, frameshift and splice site variants leading to
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premature truncation of the protein, with haploinsuficiency
believed to be the disease causing mechanism for MFDM
(Huang et al. 2016).
The identification of the EFTUD2 gene established that
MFDM is inherited in an autosomal dominant manner with
most cases (75%) the result of de novo pathogenic variants
(Huang et al. 2016). This condition is believed to be highly
penetrant with variable expressivity as some patients only dis-
play minor findings (Lines et al. 2014). As of the most recent
report in 2016, there are 107 individuals from 94 kindreds
reported with MFDM (Huang et al. 2016).
Here we report a family with three affected individuals with
MFDM that originally came to medical attention in the early
1980s. At the time, the family did not receive a definitive
diagnosis for the constellation of multiple anomalies. A mem-
ber of the family was then seen thirty years later and was
provided with a clinical and molecular diagnosis of MFDM.
The patient’s husband, in fact, had raised the possibility of the
MFDM diagnosis based on his own internet research. The
clinical description of this family adds to the literature describ-
ing the variability of theMFDMphenotype and we present the
novel pathogenic variant identified.
We also describe challenging genetic counseling issues
raised by this case including meeting genetic counseling needs
simultaneously of different family members (Bwho is the
patient^), figuring out an undiagnosed condition with the time
constraints of an ongoing pregnancy, communicating
changes in inheritance information and making decisions
about genetic testing when timing and cost are signifi-
cant considerations. This case also illustrates the impact
letters to patients and patient use of the internet can
have in making a genetic diagnosis.
Case History
In the early 1980s, our female patient (Mrs. R), then in her
early 20s, gave birth to a baby boy with multiple congenital
anomalies: tracheoesophageal fistula (TEF), microcephaly,
micrognathia, cleft palate, ventricular septal defect (VSD)
and malformation of the external ears. Mrs. R, herself, had
been born with a TEF, micrognathia, microcephaly and had
mild intellectual disability (finished high school with some
assistance). Mrs. R’s son was evaluated in a pediatric genetics
clinic when he was 4 months old. Chromosome analysis of her
son revealed a normal male karyotype (46, XY). Following
the evaluation, the family was counseled that the likely diag-
nosis was Pierre-Robin sequence which was potentially
inherited in an X-linked dominant manner, based on the fact
that Mrs. R had some of the same clinical features as her son.
In the subsequent years, Mrs. R gave birth to two more
children: a healthy daughter with no congenital anomalies
and another son who had a similar spectrum of anomalies as
the first son, but no VSD (Table 2). The family was again seen
in the pediatric genetics clinic when the younger son was
1 month of age and were counseled similarly to before; the
set of anomalies were best explained by an X-linked dominant
disorder. Both sons were given up for closed adoption within
their first year of life.
Thirty years later, Mrs. R was seen in the adult genetics
clinic with her pregnant daughter. At the time, her daughter
was approximately 13 weeks pregnant and was interested in
determining her risk to have a child with the same medical
issues as her mother and brothers. The daughter was first seen
by a prenatal genetic counselor at another hospital who re-
ferred her to our genetics clinic to determine recurrence risks.
Separately, Mrs. R’s husband also contacted our clinic’s ge-
netic counselor by email regarding his daughter’s pregnancy
and shared their family history. Through the use of the
Table 1 Major criteria of mandibulofacial dysostosis with
microcephaly (MFDM)a
1. Mandibulofacial dysostosis
Most commonly characterized by malar and maxillary hypoplasia.
Associated anomalies can also include midline cleft palate, choanal
atresia, ear anomalies (see below), and/or lacrimal atresia.
2. Microcephaly
Intellectual disability present in virtually all individuals with varied
severity.
3. Characteristic malformations of the middle/outer ear
External ears are abnormal in virtually all individuals
Middle ears are abnormal in some individuals
Hearing loss affects about 75% of individuals (80% is conductive)
4. Esophageal atresia/Tracheoesophageal fistula
5. Characteristic dysmorphic features (including micrognathia, a
relatively high nasal root with prominent ridge, everted lower lip, and
(frequently) facial asymmetry).
A diagnosis of MFDM should be suspected in individuals meeting three
or more criteria
a Lines et al. (2014)
Table 2 Features of the affected family members
Feature Mrs. R Son 1 Son 2
TEF X X X
Micrognathia X X X
Microcephaly X X X
Cleft Palate X X
Malformed Ears X X X
Ventricular Septal Defect X
Malar hypoplasia X — —
Cognitive Impairment X Xa X*
BX^ denotes presence of the feature in the particular individual
BX*^ denotes presumed present
B—^ denotes not known
a Father found a photo on the internet of his son, who was in his 20s, at a
special education school
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internet, he had located the genetic counselor they saw
30 years ago and sent her an email. This counselor had moved
out-of-state in the interim and providedMrs. R’s husband with
our clinic’s genetic counselor’s email.
In Mrs. R’s husband’s email, he notably provided the re-
sults of his own internet research on potential diagnoses. He
specifically utilized Online Mendelian Inheritance in Man
(OMIM) and GeneReviews to search for the clinical features
identified in his wife and sons and raised concern for 2 con-
ditions: MFDM and Pierre-Robin Sequence. He also inquired
about the autosomal dominant inheritance ofMFDM since the
family had been previously counseled about X-linked inheri-
tance. Additionally, Mrs. R wrote the following on our clinic’s
intake form:
BI was born with a TEF and other jaw and head shape
issues. I gave birth to a normal healthy girl. I also gave
birth to two sons with multiple birth defects, which were
more severe than mine. I was originally told that it was
an X-linked dominant trait. Thirty years later what has
been learned through research? What gene/chromosome
is responsible? Could my perfectly normal daughter be a
carrier of a recessive trait?^
This statement captured the questions we hoped to answer:
what gene change is responsible for the condition and what is
the risk to the pregnancy? When seen in our adult genetics
clinic, Mrs. R also expressed significant concern for her
daughter’s pregnancy echoing the sentiments shared above.
Given the family history, we recommended to the daughter
that her mother be evaluated and if possible, that they be seen
together. At the time of the visit to our clinic, Mrs. R was
55 years old and her daughter was 29 years old. A family
history was obtained (Fig. 1) and no additional family
members were reported to be affected. Of note, Mrs. R
reported that a paternal male second cousin also had a
TEF. He later became blind (unspecified age of onset)
and died at age 50 due to pneumonia. To the family’s
knowledge, he did not have genetic testing and no uni-
fying diagnosis was ever made.
To best provide care for both patients, our clinical team
decided to move the daughter to a different room from her
mother to obtain the medical histories and perform physical
examinations separately. This allowed us to both obtain rele-
vant information efficiently and assess the individual needs of
each patient in a confidential manner.
Mrs. R’s physical exam confirmed the microcephaly
and microretrognathia, although the latter was reportedly
more significant prior to surgery for temporomandibular
joint (TMJ) dysfunction. Additional dysmorphic features
identified included malar flattening, facial asymmetry
and a high arched palate. Mrs. R also reported trigem-
inal neuralgia and hearing loss that had worsened re-
cently. According to Mrs. R’s husband, she was seen
by an outside audiologist and ENT specialist and has
conductive hearing loss, ear canals that are smaller than
normal and a deviated septum.
Mrs. R’s daughter’s maternal family history is documented
above. Family history for her paternal side of the family was
unremarkable. The daughter had a normal physical exam. This
was the daughter’s first pregnancy and ultrasound at 12 weeks
gestation was normal.
Fig. 1 Pedigree
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Diagnostic Considerations
The family notably had copies of the clinic visit letters sent
to them 30 years prior, which provided needed documen-
tation about Mrs. R’s sons’ features and enabled us to de-
velop differential diagnoses. The initial diagnosis provided
was Pierre Robin sequence (PRS). PRS formally refers to
the association of micrognathia, glossoptosis and respira-
tory obstruction. Frequently, a secondary cleft palate also
co-occurs (Tan et al. 2013). Importantly to note, there are
multiple genetic causes of PRS including 22q11.2 deletion
syndrome, Stickler syndrome, and MFDM, and each of
these conditions can have several additional features (Tan
et al. 2013). Confirming the underlying genetic cause is
extremely important as the differential diagnoses, as noted
below, are conditions with varying inheritance patterns,
surveillance recommendations, and treatment strategies
(Lalani et al. 2006; Lines et al. 2014; Marcelis and de
Brouwer 2009; Meroni 2004; Tan et al. 2013).
The features shared by all three affected individuals in the
family (Table 2) are TEF, micrognathia, microcephaly and
intellectual disability (per parent report for the two sons).
The differential diagnoses we considered are in Table 3 and
include MFDM, Feingold syndrome, X-linked Opitz G/BBB
syndrome, CHARGE syndrome or a chromosomal
microdeletion/microduplication.
The features seen in the family met all of the major diag-
nostic criteria for MFDM. With respect to the other condi-
tions, there are key characteristic features of each condition
which were not seen in the family. Individuals with Feingold
syndrome typically have digital anomalies (Celli et al. 2003;
Marcelis and de Brouwer 2009). Females with X-linked Opitz
G/BBB syndrome rarely express a phenotype more severe
than isolated ocular hypertelorism. Additionally, males usual-
ly have hypospadias (Meroni 2004; Quaderi et al. 1997). In
terms of CHARGE syndrome, notable features missing in-
clude coloboma and choanal atresia (Hsu et al. 2014; Lalani
et al. 2006; Verloes 2005; Vissers et al. 2004). Chromosomal
microdeletions or microduplications remained a diagnostic
possibility.
Counseling Issues
Case Management: Who is the Patient?
Although this case was initiated 30 years ago when Mrs. R’s
first affected son was evaluated, it was Mrs. R’s healthy
daughter who was now inquiring about risk to her pregnancy
and had been referred to our clinic. However, even though the
daughter was referred, it was Mrs. R who needed to first have
the genetic evaluation in order to assess the risk to her
Table 3 Differential diagnoses
Feature Mandibulofacial Dysostosis






Syndromeh, i, j, k
TEF X* X* X* X
Microcephaly X* X* X
Micrognathia X* X X
Ear abnormalities X* X*
Cleft lip/palate X X X
Heart defects X X X X*
Malar hypoplasia X* X
Cognitive Impairment X X X X*
BX^ denotes presence of the feature in the particular condition
B*^ denotes major criteria for the particular condition or features seen in > 80% of individuals
a Lines et al. (2012)
b Lines et al. (2014)
c Huang et al. (2016)
d Celli et al. (2003)
eMarcelis and de Brouwer (2009)
f Quaderi et al. (1997)
gMeroni (2004)
h Vissers et al. (2004)
i Verloes (2005)
j Lalani et al. (2006)
k Hsu et al. (2014)
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daughter and the pregnancy. Recognition of the necessity of
Mrs. R being evaluated in addition to her daughter allowed us
to enact the proper work-up, make a likely diagnosis and ini-
tiate genetic testing in an effective and time-sensitive manner.
The fact that Mrs. R and her daughter were both simul-
taneously patients impacted case management and results
disclosure. Genetic testing decisions and results commu-
nication had to meet the needs of both Mrs. R and her
daughter. Fortunately, Mrs. R wanted to do the genetic
testing and share the results to help her daughter make
informed pregnancy decisions. Mrs. R was seen jointly
with her daughter to discuss her test results at which time,
genetic testing was initiated for her daughter.
We had scheduled an in-person results disclosure for
Mrs. R in order to be able to explain the results and
their implications and to have the ability to initiate ad-
ditional genetic testing as soon as possible had results
been negative. The in-person results disclosure also
allowed us to communicate the results to Mrs. R’s
daughter in a timely manner so that she could make
her genetic testing decision. Mrs. R’s daughter needed
to know her mother’s results to determine whether she
could have genetic testing for an identified familial
pathogenic variant or whether the pregnancy would be
assessed by chromosome microarray analysis and ultra-
sound evaluation, both with limitations, in the absence
of identifying a maternal pathogenic variant. Mrs. R
gave verbal consent for us during the visit to provide
her daughter with a copy of her genetic test results and
this consent was documented.
Undiagnosed Condition and Pregnancy
Mrs. R’s daughter’s 13-week pregnancy placed a time pres-
sure on this case. It is not known why genetic counseling was
not sought prior to conception or earlier in the pregnancy. In
the state where the family lived, the legal limit for pregnancy
termination is 24 weeks. When Mrs. R’s daughter was asked
about her pregnancy and whether she would make a decision
to not continue the pregnancy should it be affected, she replied
that she was unsure. She was certain that she wanted all pos-
sible information, however, to make a potential decision.
An undiagnosed condition confounds the ability to provide
a specific recurrence risk (see BRisk Assessment^ section).
Ultimately, genetic testing would be key in confirming a spe-
cific diagnosis in Mrs. R and subsequently assessing her
daughter’s risk. Because of the pregnancy, time was limited
to obtainMrs. R’s results, do additional testing if indicated and
have the option to test her daughter and/or the pregnancy if a
pathogenic variant was identified. It was possible that genetic
testing would not yield a result or would identify a variant of
uncertain significance.
Risk Assessment
Given three affected individuals, both genders, in two gener-
ations, the pattern of inheritance of the condition was consis-
tent with either autosomal dominant or X-linked inheritance
(due to the difference in severity of affected males vs. fe-
males). Therefore, if Mrs. R’s daughter was a carrier, the risk
for the pregnancy to be affected was 50%, with potentially
milder features in a female if due to X-linked inheritance.
Mrs. R’s parents and siblings were unaffected, making it
likely that the condition first manifested inMrs. R as the result
of a de novo mutation. While it is notable that a second cousin
had a TEF, he, by report, did not have any other anomalies and
had normal intelligence. This cousin’s TEF was thought to
likely be unrelated given that second cousins are fifth
degree relatives and only share approximately 3% of
their DNA as well as the fact that the four relatives
between Mrs. R and the cousin were all unaffected.
Isolated TEF/esophageal atresia occurs at an incidence
of 1/3500 individuals and it is possible that the cousin
represented an isolated case (Shaw-Smith 2006).
Testing Strategy
In determining an optimal testing strategy, two key factors
were considered: 1) whether a single test or multiple genetic
tests should be ordered and 2) result times given the ongoing
pregnancy of the daughter. Given both the clinical findings
and the family history,MFDMwas the presumptive diagnosis.
However, we could not rule out the possibility that a chromo-
somal microdeletion and/or microduplication could be the un-
derlying etiology.
After the physical exams, we brought the family together
and presented two options to confirm the diagnosis in Mrs. R:
either perform EFTUD2 molecular analysis (sequencing
followed by deletion/duplication analysis) and a chromosome
microarray analysis simultaneously or first perform EFTUD2
molecular analysis. Expedited EFTUD2molecular analysis at
extra cost was also offered. The expected turn-around time for
EFTUD2 analysis was 3–4 weeks and with expedited testing
was approximately 8 days. The family wished to start with
only EFTUD2 analysis but could not afford to pay for expe-
dited testing. A blood sample was obtained from Mrs. R and
sent for EFTUD2 analysis and at the same time, insurance
authorization was requested for both EFTUD2 analysis and
chromosome microarray analysis. Coverage for both genetic
tests was subsequently denied and unsuccessfully appealed.
Mrs. R’s daughter informed us that she would be having a
follow-up ultrasound between 15 and 16 weeks gestation.
Should her mother’s test results not yet return, we recom-
mended that the daughter consider EFTUD2molecular testing
and potentially chromosome microarray analysis for the
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pregnancy as a contingency plan, especially if ultrasound
anomalies were noted (such as polyhydramnios secondary to
esophageal atresia, cleft palate, heart defects or other anoma-
lies described in the two sons).
Novel Pathogenic Variant Identified
Mrs. R’s EFTUD2 genetic testing returned after 2 weeks and
identified a novel pathogenic variant in the EFTUD2 gene,
c.1297_1298delAT (p.Met433Valfs*17). The identified vari-
ant is predicted to result in a frameshift leading to premature
termination of the protein either in exon 13 or 14 (depending
on which protein transcript is used). Mrs. R’s daughter elected
to pursue site-specific testing as there remained the small pos-
sibility she could have inherited the EFTUD2 variant given
the variable expressivity of MFDM. Site-specific testing
returned negative and therefore Mrs. R’s daughter and the
pregnancy were not at increased risk for MFDM.
It is likely that the EFTUD2 variant identified was a de
novo variant in Mrs. R which was inherited by both of her
sons. Given that her sons were adopted out of the family, it is
unknown if they have a genetically confirmed diagnosis, but
their constellation of features is consistent with the phenotypic
spectrum of MFDM.
Discussion
This case illustrates the significant progress of clinical genet-
ics since the early 1980s, which has resulted in both the iden-
tification of numerous genetic conditions phenotypically and
molecularly. Of note, MFDM was first described in 2006
(Guion-Almeida et al. 2006) and the genes responsible for
the syndromes in our differential diagnoses were identified
only as early as 1997 (X-linked Opitz G/BBB syndrome)
and as recently as 2012 (MFDM) (Celli et al. 2003; Lines
et al. 2012; Quaderi et al. 1997; Vissers et al. 2004). These
genetic advances in syndrome identification and genetic test-
ing enabled us to give Mrs. R’s family the appropriate diag-
nosis. Our description of Mrs. R’s and her sons’ phenotypic
variability adds to the literature about MFDM. We also iden-
tified a novel pathogenic variant, thus adding to the list of
documented variants causative of MFDM.
In addition to the advances in genetics, there have been
significant changes in the way we gather information, namely
use of the internet. The internet houses databases and re-
sources about genetic syndromes, genetics clinics and pro-
viders, genetic testing and support/advocacy groups. These
sources of information are not just utilized by genetics profes-
sionals and health care providers, but by patients as well. In
this case, MFDM was first brought to our attention by Mrs.
R’s husband. He navigated through well-established online
genetics resources such as OMIM and GeneReviews to gen-
erate possible diagnoses with one of the conditions being the
correct diagnosis.
It is important, however, to recognize that most patients do
not have the training to distinguish the resources that provide
accurate information from those that do not. Additionally,
several genetics-specific informational resources avail-
able on the internet are not written for the general pub-
lic but rather for providers which greatly inhibits com-
prehension of the information by patients and their fam-
ilies. Nonetheless, this case illustrates the power of the
internet and the growing opportunities patients and their
families have in aiding in the diagnostic process.
The diagnosis was not the most challenging issue in this
case however. Mrs. R’s daughter’s pregnancy placed a time
constraint on the entire case. This time constraint was effec-
tively managed by the genetic counselor’s recognition that
while the daughter was the referred patient, her mother was
the key family member to evaluate and therefore also needed
to be seen as soon as possible.
Determining Bwho is the patient^ and recognizing that Bthe
patient^ can be more than one family member is an important
part of case management and can significantly impact the
outcome of a genetic evaluation and provision of genetic
counseling (Uhlmann 2009). In our case, we had to consider
as Bpatients^ Mrs., R, her daughter and even her daughter’s
pregnancy. BWho is the patient^ could also apply to Mrs. R’s
two more significantly affected sons, who were not available
for our evaluation but information about them from clinic
letters was critical for our evaluation of Mrs. R, decision-
making about genetic testing and provision of risk
information.
It has been a long-standing practice in genetics to send
patients letters to document the genetic counseling provided
and to have as a resource for family members (Baker et al.
2002). The letters provided by Mrs. R and her husband of the
evaluations in the 1980s were instrumental in providing us
with a clinical description of their two sons, differential diag-
noses considered, inheritance patterns discussed and testing
that was performed. Considering both sons were adopted
out, without these patient letters, we would only have had
Mrs. R’s and her husband’s report of their sons’ clinical fea-
tures since HIPAA regulations would have prohibited us from
accessing their sons’ medical records without their guardians’
permission. The letters allowed us to generate differential di-
agnoses, identify the likely diagnosis and determine testing
options prior to the family’s visit.
Decision-making about genetic testing in this case raised
the important question: what is the most important factor (i.e.
diagnostic yield, time, etc.) when performing testing?
Typically, diagnostic yield is the highest priority and one ap-
proach to achieve greater diagnostic yield is to order multiple
tests. However, selecting multiple tests is usually costlier and
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has a higher chance of yielding variants of uncertain signifi-
cance, which creates challenges in interpretation. Time is par-
amount to some patients, especially those who are pregnant or
making surgical decisions. In terms of cost, it is not uncom-
mon for genetic testing to be denied by insurance and patients
often do not have the financial resources to pay for testing
(Armstrong 2015; Jewell 2015; Secretary’s Advisory
Committee on Genetics, Health and Society 2006).
Specific to our patient and her family, a plan for testing
needed to provide the greatest opportunity to identify a mo-
lecular diagnosis and be completed in time to potentially test
the daughter/daughter’s pregnancy. The options we offered
the family reflected these two factors of diagnostic yield and
time; the option of performing EFTUD2 gene analysis and
chromosome microarray analysis concurrently cast a larger
net and valued time and yield versus EFTUD2 gene analysis
only, a less expensive option, which cast a smaller net with
need of additional testing if negative. In the end, non-
expedited EFTUD2 only analysis was pursued due to finan-
cial reasons but fortunately we were still able to obtain a time-
ly diagnostic result with this testing approach.
In this case, the MFDM diagnosis completely changed the
understanding and perception of risk of the condition.
Originally, Mrs. R and her husband thought their daughter
was Bin the clear^ because she was healthy. With new knowl-
edge, we counseled the family about the presumptive diagno-
sis of MFDM and autosomal dominant inheritance, which left
the possibility that the daughter could be very mildly affected
given variable expressivity associated with this condition, and
a potential increased risk to the pregnancy. Fortunately, it was
learned that their daughter did not carry the pathogenic vari-
ant, and there was no increased risk for the pregnancy to be
affected. In the end, this was the answer they were hoping for
and provided the most relief. Other families undergoing ge-
netic testing to identify the cause or inheritance pattern of a
disease describe similar feelings and valued the importance of
identifying the causative mutation to provide accurate risk
information for other family members (Carstens et al. 2016;
Combs et al. 2013).
Mrs. R’s genetic testing was denied insurance coverage
because it would not affect her management. Testing, howev-
er, was a necessary first step to confirm the MFDM diagnosis
molecularly in order for the daughter to have the option to test
herself/the pregnancy. This situation is analogous to many
cases in cancer genetic counseling in which it is recommended
to begin testing with an affected individual if available
(Berliner et al. 2013; Weissman et al. 2012). Even if manage-
ment of the affected individual will not be altered, identifying
the pathogenic variant is important for diagnosis confirmation,
accurate risk assessment and enables at-risk family members
to be tested.
Obtaining insurance authorization for genetic testing is a
time-involved multistep process and testing approval can be
challenging to obtain especially when results will not directly
impact patient care (Uhlmann et al. 2017). If Mrs. R had not
proceeded with genetic testing because of insurance coverage
or other issues, her daughter could have had the pregnancy
directly tested. However, this approach would have had sig-
nificant limitations. If the pregnancy had tested negative, it
would not have been known if the pregnancy was negative
because a pathogenic variant had not been inherited or nega-
tive because, even in Mrs. R, a pathogenic variant would not
be identified with today’s testing. In regards to obtaining in-
surance coverage of prenatal genetic testing, it may have been
less problematic because of the ongoing pregnancy (Deverka
and Dreyfus 2014; Graf et al. 2013; Secretary’s Advisory
Committee on Genetics, Health and Society 2006). If Mrs.
R’s daughter did not have insurance coverage for genetic test-
ing and could not afford the out of pocket expense, evaluating
the pregnancy would have been limited to using the
screening ultrasound that is recommended in all preg-
nancies at approximately 18 weeks’ gestation, and
others as clinically indicated (American College of
Obstetricians and Gynecologists 2016), in the hopes of
identifying some of the MFDM clinical features.
This case effectively demonstrates the quintessential fea-
ture about clinical genetics practice: genetics affects not just
the patient, but the family. If we had only seenMrs. R’s daugh-
ter in our clinic, our evaluation would have been limited and
our testing would likely have either been unfruitful or unin-
formative. Despite this being an extreme case of almost thirty
years separating the clinic visits, this case also highlights the
importance of encouraging follow-up. Ensuring patients
follow-up with genetics, especially given advances in genetic
testing, improves the possibility of obtaining a molecular di-
agnosis and gives some patients what is most needed: a name
for their medical condition.
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